Recursion Pharmaceuticals Stock Hits Day Low of $3.21 Amid Price Pressure

Recursion Pharmaceuticals, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, experienced significant volatility on June 5, 2026, with its stock price declining by 12.76%. The stock reached an intraday low of USD 3.21, reflecting ongoing challenges in its market performance. Over the past year, Recursion has faced a notable decline of 27.46%, significantly underperforming the S&P 500, which gained 24.32% during the same period. The company's performance metrics indicate a concerning trend, with profits plummeting by 89.4% over the last year. This consistent underperformance is evident over a three-year horizon, where the stock has generated negative returns, contrasting sharply with the S&P 500's positive trajectory. Recursion's financial indicators further highlight its struggles, including a return on equity of -57.01% and a price-to-book ratio of 1.37. With no dividend yield and a debt-to-equity ratio of -0.63, the company continues to navigate a challenging landscape in the biotechnology sector.